Bio-Rad Laboratories, Inc.
BIO-B
New York Stock Exchange324.28
USD
+14.91
- -
Bio-Rad Laboratories, Inc.
BIO-B
(New York Stock Exchange)
Recent
price
324.28
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Bio-Rad Laboratories, Inc. (NYSE: BIO, BIO-B) develops, manufactures, and markets specialized technological products and solutions for life science research and clinical diagnostics markets worldwide. The company operates through two primary segments: Life Science, which offers instruments, software, consumables, reagents, and content for cell biology, gene expression and expression, protein purification and quantitation, drug discovery and manufacture, food safety testing, science education, chromatography systems and media, Droplet Digital PCR (ddPCR) platforms including the QX Continuum and QX700 series, flow cytometry antibodies, electrophoresis systems, single-cell analysis tools, and real-time PCR instruments such as CFX Opus; and Clinical Diagnostics, which provides quality controls like InteliQ and Exact Diagnostics, autoimmune testing via IFA, EIA, and multiplex assays, diabetes testing with NGSP-certified HPLC systems for HbA1c, infectious disease assays for HIV, HCV, HBV, and syphilis, blood typing and screening systems including IH-500 and IH-1000, cardiac controls, and Unity QC data management solutions. Bio-Rad also supplies food and beverage safety testing kits for pathogens, cannabis and water quality testing, and veterinary diagnostics, alongside classroom education kits for biotechnology, pGLO transformation, and CRISPR gene editing. Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, the company maintains global operations across the U.S., Europe, Asia, Canada, and Latin America, employing approximately 7,700 people and generating $2.57 billion in 2024 revenue. Recent developments include the 2025 acquisition of Stilla Technologies for $225 million plus up to $50 million in milestones to bolster its digital PCR portfolio with next-generation systems for oncology, infectious diseases, and genetic research; the launch of four new ddPCR platforms such as QX Continuum for translational research with four-color multiplexing; investments in Geneoscopy and OncoCyte to advance ddPCR in clinical testing; and 2024 acquisitions of Saber Bio for droplet technology in antibody discovery along with expanded ddPCR kits for drug manufacturing, oncology, food safety, and products like ChemiDoc Go imaging system and ddSEQ single-cell RNA-Seq kit.
Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause
Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings
Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit
Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products
Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip
Bio-Rad Labs cuts 2023 revenue growth forecast as biotechs cut spending